Evidence map›Paper›PMID 41352088›Full record

Trial reportDrug and alcohol dependence2026

Quality of life and treatment effectiveness direct and indirect effects on cocaine abstinence outcomes during cocaine use disorder treatment.

Crystal L Smith, Sterling M McPherson, Nicole Rodin, Sean E Hovland, Nicole Akana, Andre Qc Miguel, John Marsden, Andrew J Saxon

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Drug and alcohol dependence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Crystal L SmithElson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Laboratory for Innovations in Therapeutics, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States. Electronic address: Crystal.lederhos@wsu.edu.
Sterling M McPhersonElson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Laboratory for Innovations in Therapeutics, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; Department of Psychiatry and Behavioral Science, University of Washington School of Medicine, Seattle, WA, United States.
Nicole RodinLaboratory for Innovations in Therapeutics, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States; College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, United States.
Sean E HovlandElson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Laboratory for Innovations in Therapeutics, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States.
Nicole AkanaElson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Laboratory for Innovations in Therapeutics, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States.
Andre Qc MiguelElson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Laboratory for Innovations in Therapeutics, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States.
John MarsdenAddictions Department, School of Academic Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, United Kingdom.
Andrew J SaxonDepartment of Psychiatry and Behavioral Science, University of Washington School of Medicine, Seattle, WA, United States.

Funding

Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
NIDA NIH HHS UG1 DA013714
6 · The paper itself

Abstract

backgroundPatient-perceived Quality-of-Life (QOL) and treatment effectiveness (TEA) have previously been shown to be positively associated with better substance use treatment outcomes.

objectivesThis study examined potentially causal relationships amongst QOL, TEA, and cocaine abstinence.

methodsSecondary data analyses (CTN-0148) were conducted on the NIDA Clinical Trial Network study, Cocaine Use Reduction with Buprenorphine (CTN-0048). N = 301 participants with DSM-IV cocaine dependence and opioid use history were administered injectable naltrexone and randomized to one of three buprenorphine/naloxone doses, 4mg/1mg, 16mg/4mg or placebo. Mediation models estimated direct and indirect effects amongst QOL, TEA, and cocaine abstinence.

resultsThe QOL Environment domain exerted a significant indirect effect (B=0.01, SE=0.01, 95 % CI=[0.00, 0.02]) on cocaine abstinence and a direct effect on TEA (B=0.57, SE=0.22, 95 % CI=[0.16, 1.01]). Other QOL domains and individual QOL items exerted no statistically significant direct effects on cocaine abstinence. Overall QOL exerted a significant direct effect on TEA (95 % CI=[0.32, 2.45]) along with a significant indirect effect on cocaine abstinence (95 % CI=[0.01, 0.05]). TEA had a significant positive direct effect on cocaine abstinence (95 % CI=[0.01, 0.02]).

conclusionOverall QOL and environmental QOL are related to treatment response through their relationship with patients' perception of treatment effectiveness. TEA is directly related to cocaine abstinence at the end of treatment. QOL and TEA measures may serve as indicators of a need for additional support within care plans. These findings highlight the impact of a patient's sense of well-being and their perceived treatment effectiveness on biochemically validated cocaine abstinence.

Indexed as

Cocaine-Related DisordersNarcotic AntagonistsQuality of LifeAdultBuprenorphineBuprenorphine, Naloxone Drug CombinationFemaleHumansMaleMiddle AgedNaltrexoneOpiate Substitution TreatmentTreatment OutcomeBuprenorphineBuprenorphine, Naloxone Drug CombinationNaltrexoneNarcotic AntagonistsBuprenorphineClinical trials networkCocaine use disorderNaloxoneQuality of lifeTreatment effectiveness

Identifiers

PMID41352088
PMCPMC13334835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.